Clofazimine

Revision as of 23:58, 8 August 2012 by WikiBot (talk | contribs) (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
Jump to navigation Jump to search
Clofazimine
File:Clofazimine.svg
Clinical data
ATC code
Pharmacokinetic data
Elimination half-life70 days
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC27H22Cl2N4
Molar mass473.396 g/mol

WikiDoc Resources for Clofazimine

Articles

Most recent articles on Clofazimine

Most cited articles on Clofazimine

Review articles on Clofazimine

Articles on Clofazimine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Clofazimine

Images of Clofazimine

Photos of Clofazimine

Podcasts & MP3s on Clofazimine

Videos on Clofazimine

Evidence Based Medicine

Cochrane Collaboration on Clofazimine

Bandolier on Clofazimine

TRIP on Clofazimine

Clinical Trials

Ongoing Trials on Clofazimine at Clinical Trials.gov

Trial results on Clofazimine

Clinical Trials on Clofazimine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Clofazimine

NICE Guidance on Clofazimine

NHS PRODIGY Guidance

FDA on Clofazimine

CDC on Clofazimine

Books

Books on Clofazimine

News

Clofazimine in the news

Be alerted to news on Clofazimine

News trends on Clofazimine

Commentary

Blogs on Clofazimine

Definitions

Definitions of Clofazimine

Patient Resources / Community

Patient resources on Clofazimine

Discussion groups on Clofazimine

Patient Handouts on Clofazimine

Directions to Hospitals Treating Clofazimine

Risk calculators and risk factors for Clofazimine

Healthcare Provider Resources

Symptoms of Clofazimine

Causes & Risk Factors for Clofazimine

Diagnostic studies for Clofazimine

Treatment of Clofazimine

Continuing Medical Education (CME)

CME Programs on Clofazimine

International

Clofazimine en Espanol

Clofazimine en Francais

Business

Clofazimine in the Marketplace

Patents on Clofazimine

Experimental / Informatics

List of terms related to Clofazimine


Clofazimine is a fat-soluble riminophenazine dye used in combination with rifampicin and dapsone as multidrug therapy (MDT) for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum (ENL). (From AMA Drug Evaluations Annual, 1993, p1619).

History

Clofazimine, initially known as B663, was first synthesised in 1954 by a team led by Dr Vincent Barry at Trinity College, Dublin as an anti-tuberculosis drug. The drug proved ineffective against tuberculosis but in 1959 a researcher named Chang identified its effectiveness against leprosy. After clinical trials in Nigeria and elsewhere during the 1960s, some sponsored by the Swiss pharmaceutical company Geigy (today member of the Novartis group of drug producers), the product was launched in 1969 as Lamprene.

The U.S. government named Clofazimine an orphan drug in June 1986. Geigy gained FDA approval for the drug in December 1986.

Supply

Clofazimine is marketed under the trade name Lamprene® by Novartis. One of the only suppliers of Clofazimine Active Pharmaceutical Ingredient in the world is Sangrose Laboratories, located at Mavelikara in the southern Indian state of Kerala.

Metabolism

Clofazimine has a very long half life of about 70 days. Clofazimine produces pink to brownish skin pigmentation in 75-100% of patients within a few weeks.

External links

Template:WH Template:WS